Published in Addiction on September 01, 2007
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis (2011) 3.13
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet (2010) 2.26
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Public health and international drug policy. Lancet (2016) 1.71
Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction (2011) 1.62
HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open (2012) 1.49
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction (2015) 1.42
Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health (2012) 1.35
Associations between herpes simplex virus type 2 and HCV With HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. Am J Public Health (2011) 1.32
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend (2010) 1.21
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One (2014) 1.16
HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS (2016) 1.16
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringes. Am J Public Health (2010) 1.11
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One (2012) 1.09
Prevention and treatment produced large decreases in HIV incidence in a model of people who inject drugs. Health Aff (Millwood) (2014) 1.08
A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals. Drug Alcohol Depend (2008) 1.05
Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. J Virol (2012) 1.02
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat (2014) 1.01
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One (2014) 0.99
Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health (2009) 0.98
Retention and HIV seroconversion among drug users on methadone maintenance treatment in Yunnan, China. Public Health Action (2014) 0.97
Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health (2011) 0.96
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol (2009) 0.95
HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health (2010) 0.95
Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health (2013) 0.95
Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr (2010) 0.94
A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis (2009) 0.93
Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med (2014) 0.91
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS (2015) 0.90
Estonia at the threshold of the fourth decade of the AIDS era in Europe. AIDS Res Hum Retroviruses (2011) 0.89
30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs. Adv Prev Med (2013) 0.88
A needle in the haystack - the dire straits of needle exchange in Hungary. BMC Public Health (2016) 0.88
Combined HIV prevention, the New York City condom distribution program, and the evolution of safer sex behavior among persons who inject drugs in New York City. AIDS Behav (2014) 0.87
In the clinic. Hepatitis C. Ann Intern Med (2008) 0.84
Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduct J (2015) 0.84
Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? PLoS One (2015) 0.84
HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. J Acquir Immune Defic Syndr (2015) 0.83
Benefits of concurrent syringe exchange and substance abuse treatment participation. J Subst Abuse Treat (2011) 0.83
Multilevel analysis of HIV related risk behaviors among heroin users in a low prevalence community. BMC Public Health (2009) 0.83
Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open (2015) 0.82
How relevant is Bellagio statement of principles on social justice and influenza to Africa? Croat Med J (2007) 0.82
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug Alcohol Depend (2016) 0.82
Psychiatric distress, risk behavior, and treatment enrollment among syringe exchange participants. Addict Behav (2010) 0.81
Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis (2015) 0.80
Harm reduction and equity of access to care for French prisoners: a review. Harm Reduct J (2008) 0.80
Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol (2012) 0.80
Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes. Drug Alcohol Depend (2011) 0.80
Factors responsible for mortality variation in the United States: A latent variable analysis. Demogr Res (2014) 0.80
Hepatitis C avoidance in injection drug users: a typology of possible protective practices. PLoS One (2013) 0.80
Estimating the Cost-Effectiveness of HIV Prevention Programmes in Vietnam, 2006-2010: A Modelling Study. PLoS One (2015) 0.80
Vulnerability to HIV infection among female drug users in Kathmandu Valley, Nepal: a cross-sectional study. BMC Public Health (2013) 0.79
Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands. Harm Reduct J (2010) 0.79
Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis. Harm Reduct J (2014) 0.79
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78
More than just needles: an evidence-informed approach to enhancing harm reduction supply distribution in British Columbia. Harm Reduct J (2008) 0.78
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev (2016) 0.78
Factors affecting repeated cessations of injecting drug use and relapses during the entire injecting career among the Edinburgh Addiction Cohort. Drug Alcohol Depend (2015) 0.78
A cross-sectional study of public attitudes towards safer drug use practices in British Columbia, Canada. Subst Abuse Treat Prev Policy (2013) 0.78
High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance. BMC Infect Dis (2015) 0.77
A treatment reengagement intervention for syringe exchangers. J Subst Abuse Treat (2011) 0.77
Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis (2015) 0.77
Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine. Cost Eff Resour Alloc (2014) 0.77
Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health (2017) 0.75
Effects of combination approach on harm reduction programs: the Taiwan experience. Harm Reduct J (2016) 0.75
Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction (2017) 0.75
Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J (2014) 0.75
Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions. Subst Abuse Treat Prev Policy (2014) 0.75
Drug users in Amsterdam: are they still at risk for HIV? PLoS One (2013) 0.75
Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concern. BMC Public Health (2015) 0.75
Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam. Int J Drug Policy (2016) 0.75
How understanding and application of drug-related legal instruments affects harm reduction interventions in Cambodia: a qualitative study. Harm Reduct J (2017) 0.75
A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011. Int J Drug Policy (2016) 0.75
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J (2017) 0.75
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care (2016) 0.75
Getting it right when budgets are tight: Using optimal expansion pathways to prioritize responses to concentrated and mixed HIV epidemics. PLoS One (2017) 0.75
Global overview of injecting drug use and HIV infection among injecting drug users. AIDS (2004) 5.45
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
HIV in central and eastern Europe. Lancet (2003) 3.82
Preventing AIDS in drug addicts in Amsterdam. Lancet (1986) 3.77
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (1988) 3.50
An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat (2005) 3.46
Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS (1998) 3.08
Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse (2006) 2.83
Implications of methadone maintenance for theories of narcotic addiction. JAMA (1988) 2.28
Sexual transmission of HCV between spouses. Am J Gastroenterol (2005) 2.08
Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect (2000) 1.94
Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust (2000) 1.92
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS (1998) 1.46
Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study. Addiction (2000) 1.38
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction (2005) 1.25
Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS (2006) 1.18
Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug Alcohol Depend (2006) 1.08
The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities. Int J Epidemiol (1999) 1.05
Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol (2001) 0.99
A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care (2000) 0.95
Sex and hepatitis C. Am J Gastroenterol (2005) 0.92
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol (2009) 2.31
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia. AIDS (2009) 2.09
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS (2009) 2.07
The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS (2003) 1.93
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS (2004) 1.82
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend (2005) 1.69
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Unravelling the impact of ethnicity on health in Europe: the HELIUS study. BMC Public Health (2013) 1.59
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis (2014) 1.59
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis (2014) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Estimating the transfusion transmission risk of Q fever. Transfusion (2014) 1.42
Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol (2005) 1.39
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. AIDS (2007) 1.38
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (2011) 1.31
Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. Sex Transm Dis (2008) 1.26
High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. Sex Transm Dis (2012) 1.25
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis (2013) 1.23
Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis (2011) 1.22
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS (2006) 1.18
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol (2005) 1.14
HIV incidence and HIV testing behavior in men who have sex with men: using three incidence sources, The Netherlands, 1984-2005. AIDS (2007) 1.13
HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. Blood (2011) 1.13
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology (2012) 1.13
Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS (2004) 1.11
Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. BMC Infect Dis (2011) 1.10
Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS (2004) 1.10
Decline in prevalence of HIV-1 infection and syphilis among young women attending antenatal care clinics in Addis Ababa, Ethiopia: results from sentinel surveillance, 1995-2001. J Acquir Immune Defic Syndr (2002) 1.10
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
Lay diagnosis of causes of death for monitoring AIDS mortality in Addis Ababa, Ethiopia. Trop Med Int Health (2004) 1.05
Natural history of HIV-control since seroconversion. AIDS (2013) 1.02
Monitoring cause-specific adult mortality in developing countries: a comparison of data sources for Addis Ababa and its implications for policy and research. Soc Sci Med (2005) 1.02
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses (2010) 1.02
Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. J Virol (2012) 1.02
Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol (2011) 1.00
Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS (2004) 1.00
HIV and sexual risk behavior among commercial sex workers in the Netherlands. Arch Sex Behav (2008) 1.00
Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther (2006) 0.99
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. J Acquir Immune Defic Syndr (2003) 0.99
Hospitalizations during a measles epidemic in the Netherlands, 1999 to 2000. Pediatr Infect Dis J (2002) 0.99
The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. AIDS (2002) 0.98
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health (2003) 0.98
Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. Clin Infect Dis (2010) 0.97
Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology (2004) 0.96
Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. AIDS (2015) 0.96
Recreational drug use during sex and sexually transmitted infections among clients of a city sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Dis (2012) 0.96
Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 0.96
Targeted vaccination programme successful in reducing acute hepatitis B in men having sex with men in Amsterdam, the Netherlands. J Hepatol (2013) 0.96
Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. Sex Transm Infect (2010) 0.95
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS (2016) 0.95
Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study. Eur Addict Res (2009) 0.94
Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One (2013) 0.94
Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS (2011) 0.94
Can migrants from high-endemic countries cause new HIV outbreaks among heterosexuals in low-endemic countries? AIDS (2010) 0.93
Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS Res Hum Retroviruses (2003) 0.93
Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J Infect Dis (2011) 0.92
Primary HIV-1 subtype C infection in Ethiopia. J Acquir Immune Defic Syndr (2002) 0.92
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data. AIDS (2012) 0.91
Stabilizing incidence of hepatitis C virus infection among men who have sex with men in Amsterdam. J Acquir Immune Defic Syndr (2014) 0.90
Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS (2014) 0.90
Do HIV disease progression and HAART response vary among injecting drug users in Europe? Eur J Epidemiol (2005) 0.90
Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol (2012) 0.90
HIV transmission patterns among The Netherlands, Suriname, and The Netherlands Antilles: a molecular epidemiological study. AIDS Res Hum Retroviruses (2010) 0.89
Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands. PLoS One (2013) 0.89
Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One (2013) 0.88